SCHEMBL723374

SCHEMBL723374

COc1ccc(OCCN)cc1-c1ccnc2cc(-c3cc(OC)c(OC)c(OC)c3)oc12

nearest known ligand 0.39

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PDE4C Q08493 1/20 0.39
CYP1B1 Q16678 4/20 0.39
CYP1A1 P04798 3/20 0.39
CYP1A2 P05177 3/20 0.39
BRD4 O60885 2/20 0.37
FYN P06241 3/20 0.36
RPS6KA2 Q15349 1/20 0.35
ADORA2A P29274 1/20 0.35
MAPT P10636 1/20 0.35
SYK P43405 1/20 0.35
PTGES O14684 1/20 0.35
ALOX5 P09917 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15210374 0.92 CYP1B1 (0.38) PDE4CCYP1B1CYP1A1CYP1A2BRD4
SCHEMBL721530 0.87 PDE4C (0.47) PDE4CFYNADORA2A
SCHEMBL15212654 0.85 PDE4C (0.41) PDE4CCYP1B1CYP1A1CYP1A2BRD4
SCHEMBL10267310 0.85 PDE4C (0.44) PDE4CCYP1B1CYP1A1RPS6KA2MAPT
SCHEMBL723398 0.81 CALCRL (0.50) PDE4CCYP1B1CYP1A1CYP1A2BRD4
SCHEMBL15210548 0.81 PDE4C (0.37) PDE4CCYP1B1CYP1A1CYP1A2BRD4
SCHEMBL721632 0.81 PDE4C (0.41) PDE4CCYP1B1CYP1A1CYP1A2BRD4
SCHEMBL723093 0.80 PDE4C (0.55) PDE4CCYP1B1CYP1A1CYP1A2BRD4
SCHEMBL16626262 0.80 BRD4 (0.39) PDE4CBRD4FYN
SCHEMBL723261 0.80 PDE4C (0.43) PDE4CCYP1B1CYP1A1CYP1A2BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP claimed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US claimed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US claimed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP claimed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO claimed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB PDE4C 2858/4885CYP1B1 915/4885CYP1A1 452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.